0001209191-24-002074.txt : 20240123 0001209191-24-002074.hdr.sgml : 20240123 20240123165839 ACCESSION NUMBER: 0001209191-24-002074 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230711 FILED AS OF DATE: 20240123 DATE AS OF CHANGE: 20240123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Overdorf Michael CENTRAL INDEX KEY: 0001818522 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39402 FILM NUMBER: 24553268 MAIL ADDRESS: STREET 1: C/O ANNEXON, INC. STREET 2: 180 KIMBALL WAY, SUITE 200 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Annexon, Inc. CENTRAL INDEX KEY: 0001528115 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 275414423 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1400 SIERRA POINT PARKWAY STREET 2: BLDG C, SUITE 200 CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: (650)-822-5500 MAIL ADDRESS: STREET 1: 1400 SIERRA POINT PARKWAY STREET 2: BLDG C, SUITE 200 CITY: BRISBANE STATE: CA ZIP: 94005 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-07-11 0 0001528115 Annexon, Inc. ANNX 0001818522 Overdorf Michael C/O ANNEXON, INC. 1400 SIERRA POINT PKWY, BLDG C, STE 200 BRISBANE CA 94005 0 1 0 0 EVP & Chief Business Officer 0 Common Stock 2023-07-11 4 S 0 978 3.8361 D 45802 D The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). This transaction was executed in multiple trades in prices ranging from $3.72 to $3.90, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Includes 33,559 RSUs. Late filing being made as a result of an administrative oversight. /s/ Jennifer Lew, as Attorney-in-Fact 2024-01-23